AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ALPROSTADIL

10 registrations across 5 African markets— 5 active

Markets with ALPROSTADIL

Recent registrations

Brand / ProductMarketHolderStatusExpires
CAVERJECT 20 ug🇿🇦South AfricaPfizer Laboratories (Pty) LtdsuspendedJun 2022
EDEX
Pdre p.prep.injectable / 10 µG/ml
🇹🇳TunisiaSCHWARZ PHARMAexpiredJul 2012
EDEX
Pdre p.prep.injectable / 20 µG/ml
🇹🇳TunisiaSCHWARZ PHARMAexpiredJul 2012
CAVERJECT 20MCG STERILE POWDER AND DILUENT FOR INJECTION
STERILE POWDER AND DILUENT FOR INJECTION
🇲🇼MalawiexpiredJun 2004
CAVERJECT 20MCG STERILE POWDER AND DILUENT FOR INJECTION
STERILE POWDER AND DILUENT FOR INJECTION
🇲🇼MalawiexpiredJun 2003
PROSTIN VR🇿🇦South AfricaPfizer Laboratories (Pty) LtdactiveJan 1900
EDEX
poudre pour préparation injectable / 10 mcg / ml
🇸🇳SenegalSCHWARZ PHARMAactive
EDEX
poudre pour préparation injectable / 20 mcg/ml
🇸🇳SenegalSCHWARZ PHARMAactive
CAVERJECT
POUDRE POUR SOLUTION INJECTABLE
🇲🇦Moroccoactive
CAVERJECT
POUDRE POUR SOLUTION INJECTABLE
🇲🇦Moroccoactive

ALPROSTADIL in Africa — Regulatory Overview

ALPROSTADIL is registered across 5 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Morocco, Malawi, Senegal, Tunisia and 1 more. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 5 (50%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.